Selected Grants
Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness
ResearchSignificant Contributor · Awarded by National Institutes of Health · 2022 - 2027Duke Center for ADHD in Girls/Women
ResearchInvestigator · Awarded by Gratis Foundation · 2021 - 2025Duke Women's Reproductive Health Research Scholars
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2025Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024Scalable Computational Platform For Active Closed-Loop Behavioral Coding in Autism Spectrum Disorder
ResearchConsultant · Awarded by National Institutes of Health · 2019 - 2024Increasing the health equity and population-level impact of a digital therapeutic for smokers with psychiatric illness
ResearchSignificant Contributor · Awarded by National Institutes of Health · 2022 - 2027Duke Center for ADHD in Girls/Women
ResearchInvestigator · Awarded by Gratis Foundation · 2021 - 2025Duke Women's Reproductive Health Research Scholars
Inst. Training Prgm or CMEMentor · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2025Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024Scalable Computational Platform For Active Closed-Loop Behavioral Coding in Autism Spectrum Disorder
ResearchConsultant · Awarded by National Institutes of Health · 2019 - 2024Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD
ResearchMentor · Awarded by National Institutes of Health · 2016 - 2022Paternal Transgenerational Epigenetic Legacy from Use of Cannabis
ResearchCo-Project Leader · Awarded by John Templeton Foundation · 2017 - 2022Maternal obesity, child executive functions and child weight gain
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2022Targeting reward dysfunction as a mechanism to improve smoking cessation
ResearchCo-Mentor · Awarded by National Institutes of Health · 2016 - 2022Mobile health interventions for varenicline adherence among HIV-positive smokers
ResearchCo-Mentor · Awarded by National Institutes of Health · 2017 - 2021Increasing Motivation in ADHD Via Self-activation of VTA
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2016 - 2021Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2017 - 2020Modeling the Neurobehavioral Basis of Extrinsic and Volitional Motivation in ADHD
FellowshipCo-Sponsor · Awarded by National Institutes of Health · 2017 - 2020Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers
ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020A randomized, sham-controlled, crossover study to evaluate the effects of noise cancelling headphones on neurocognitive and academic outcomes in children and adolescents diagnosed with ADHD
Clinical TrialPrincipal Investigator · Awarded by Bose Corporation · 2017 - 2019Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2019A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Laboratory Classroom Study with KP415 in Children with Attention-Deficit/Hyperactivity Disorder
Clinical TrialPrincipal Investigator · Awarded by KemPharm, Inc · 2017 - 2019A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed with Attention-deficit/Hyperactivity Disorder
Clinical TrialPrincipal Investigator · Awarded by Shire Pharmaceutical Development US Inc. · 2015 - 2019mSMART: Mobile App based Personalized Solutions and Tools for Medication Adherence of Rx Pills
ResearchCo Investigator · Awarded by Intelligent Automation Inc. · 2014 - 2019Protecting Neurodevelopment in Latino Migrant Children by Reduced Exposure to Organophosphate Pesticides
ResearchCollaborator · Awarded by National Institutes of Health · 2017 - 2019RP-BP-EF004: A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Children Ages 4-5 Years Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Rhodes Pharmaceuticals L.P. · 2016 - 2018Behavioral and genetic mechanisms of smoking risk in individuals with ADHD
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2018Smoking Abstinence in ADHD and non-ADHD Smokers: Assessing the Role of Emotion Dysregulation
ResearchMentor · Awarded by National Institutes of Health · 2012 - 2018A Pharmacokinetic Study of Aptensio XR¿ (Methylphenidate Hydrochloride) Extended-Release capsules in Male or Female Pre-School Children 4 to Under 6 years of age with ADHD in Fed Condition
Clinical TrialPrincipal Investigator · Awarded by Rhodes Pharmaceuticals L.P. · 2015 - 2018RP-BP-EF003: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4 to Under 6 Years Diagnosed with ADHD
Clinical TrialPrincipal Investigator · Awarded by Rhodes Pharmaceuticals L.P. · 2016 - 2018Characterizing ADHD using a behavioral model of dopamine function
ResearchMentor · Awarded by Brain and Behavior Research Foundation · 2016 - 2018Pilot Project: Effects of Cannabis on the Epigenome of Humans and Rats
ResearchCo-Project Leader · Awarded by John Templeton Foundation · 2016 - 2017A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention Deficit/Hyperactivity Disorder
Clinical TrialPrincipal Investigator · Awarded by Shire Pharmaceutical Development US Inc. · 2015 - 2017mGluR Mutations in ADHD
Clinical TrialPrincipal Investigator · Awarded by Medgenics, Inc · 2016 - 2017A 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2017A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2017A Ph. 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & ER Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post waking, Early Mor
Clinical TrialPrincipal Investigator · Awarded by Ironshore Pharmaceuticals & Development, Inc · 2015 - 2016An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2016SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Sunovion Pharmaceuticals, Inc · 2014 - 2016A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Neurovance · 2015 - 2016A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) with ADHD in a Laboratory Classroom
Clinical TrialPrincipal Investigator · Awarded by Arbor Pharmaceuticals, Inc · 2013 - 2015A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age with Attention Deficit Hyperactivity Disorder
Clinical TrialPrincipal Investigator · Awarded by Sunovion Pharmaceuticals, Inc · 2015 - 2015A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS
Clinical TrialPrincipal Investigator · Awarded by Purdue Pharma L.P. · 2014 - 2015A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS
Clinical TrialPrincipal Investigator · Awarded by Purdue Pharma L.P. · 2014 - 2015A SIX-MONTH, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF PRC-063 IN ADULTS AND ADOLESCENTS WITH ADHD
Clinical TrialPrincipal Investigator · Awarded by Purdue Pharma L.P. · 2014 - 2015A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder (CEES ADHD)
Clinical TrialPrincipal Investigator · Awarded by Ironshore Pharmaceuticals & Development, Inc · 2014 - 2015A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)
Clinical TrialPrincipal Investigator · Awarded by Alcobra Ltd. · 2014 - 2015Amphetamine Extended-Release Oral Suspension in the Treatment of Children with ADHD: A Laboratory School Study
Clinical TrialPrincipal Investigator · Awarded by Tris Pharma, Inc. · 2014 - 2015Project 1: Evaluating New Nicotine Standards in Cigarettes - Supplement
ResearchCo Investigator · Awarded by University of Pittsburgh · 2013 - 2014Elucidating links between ADHD symptoms and tobacco/alcohol use trajectories
ResearchAdvisor · Awarded by National Institutes of Health · 2010 - 2014Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence
ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2014A randomized, multicenter, double-blind, placebo-controlled, parallel group study of NT0102 Methylphenidate Polistirex Extended-Release Oral Disintegrating Tablets in children w/ADHD
Clinical TrialPrincipal Investigator · Awarded by Neos Therapeutics, Inc · 2013 - 2014Sensitivity to smoking reinforcement in women: menstrual cycle effects
ResearchCollaborator · Awarded by National Institutes of Health · 2011 - 2013Ecological Momentary Assessment of Ad Lib Smoking in ADHD Smokers
ResearchCollaborator · Awarded by National Institutes of Health · 2011 - 2012Genetic basis of smoking abstinence, smoking reinforcement, and inhibitory control
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2012Smoking reinforcement in adults with and without ADHD
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2012Follow up of the PATS sample
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2004 - 2010Candidate Gene Analysis of Persistent AD/HD
ResearchCo Investigator · Awarded by National Institutes of Health · 2004 - 2010Mechanisms of Nicotine Dependence in ADHD Adults
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2007 - 2009Development of Behavorial Screening Tools for ADHD
ResearchPrincipal Investigator · Awarded by Environmental Protection Agency · 2005 - 2008Methylphenidate Abuse Potential in ADHD Adults
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2005 - 2008Functional Neuroanatomical Deficits in ADHD Families
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2002 - 2006Attention Deficit Hyperactivity Disorder
ResearchPrincipal Investigator · Awarded by Environmental Protection Agency · 2003 - 2004External Relationships
- Akili Interactive
- Aura
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.